Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy

Subhankar Biswas, C. Mallikarjuna Rao

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Addition of chemical tags on the DNA and modification of histone proteins impart a distinct feature on chromatin architecture. With the advancement in scientific research, the key players underlying these changes have been identified as epigenetic modifiers of the chromatin. Indeed, the plethora of enzymes catalyzing these modifications, portray the diversity of epigenetic space and the intricacy in regulating gene expression. These epigenetic players are categorized as writers: that introduce various chemical modifications on DNA and histones, readers: the specialized domain containing proteins that identify and interpret those modifications and erasers: the dedicated group of enzymes proficient in removing these chemical tags. Research over the past few decades has established that these epigenetic tools are associated with numerous disease conditions especially cancer. Besides, with the involvement of epigenetics in cancer, these enzymes and protein domains provide new targets for cancer drug development. This is certain from the volume of epigenetic research conducted in universities and R&D sector of pharmaceutical industry. Here we have highlighted the different types of epigenetic enzymes and protein domains with an emphasis on methylation and acetylation. This review also deals with the recent developments in small molecule inhibitors as potential anti-cancer drugs targeting the epigenetic space.

Original languageEnglish
Pages (from-to)8-24
Number of pages17
JournalEuropean Journal of Pharmacology
Volume837
DOIs
Publication statusPublished - 15-10-2018

Fingerprint

Epigenomics
Neoplasms
Enzymes
Therapeutics
Chromatin
Histone Code
Research
DNA
Drug Industry
Drug Delivery Systems
Acetylation
Histones
Methylation
Gene Expression
Pharmaceutical Preparations
Protein Domains
Proteins

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

@article{8c436949837649ca920b0458f54a1347,
title = "Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy",
abstract = "Addition of chemical tags on the DNA and modification of histone proteins impart a distinct feature on chromatin architecture. With the advancement in scientific research, the key players underlying these changes have been identified as epigenetic modifiers of the chromatin. Indeed, the plethora of enzymes catalyzing these modifications, portray the diversity of epigenetic space and the intricacy in regulating gene expression. These epigenetic players are categorized as writers: that introduce various chemical modifications on DNA and histones, readers: the specialized domain containing proteins that identify and interpret those modifications and erasers: the dedicated group of enzymes proficient in removing these chemical tags. Research over the past few decades has established that these epigenetic tools are associated with numerous disease conditions especially cancer. Besides, with the involvement of epigenetics in cancer, these enzymes and protein domains provide new targets for cancer drug development. This is certain from the volume of epigenetic research conducted in universities and R&D sector of pharmaceutical industry. Here we have highlighted the different types of epigenetic enzymes and protein domains with an emphasis on methylation and acetylation. This review also deals with the recent developments in small molecule inhibitors as potential anti-cancer drugs targeting the epigenetic space.",
author = "Subhankar Biswas and Rao, {C. Mallikarjuna}",
year = "2018",
month = "10",
day = "15",
doi = "10.1016/j.ejphar.2018.08.021",
language = "English",
volume = "837",
pages = "8--24",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy. / Biswas, Subhankar; Rao, C. Mallikarjuna.

In: European Journal of Pharmacology, Vol. 837, 15.10.2018, p. 8-24.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy

AU - Biswas, Subhankar

AU - Rao, C. Mallikarjuna

PY - 2018/10/15

Y1 - 2018/10/15

N2 - Addition of chemical tags on the DNA and modification of histone proteins impart a distinct feature on chromatin architecture. With the advancement in scientific research, the key players underlying these changes have been identified as epigenetic modifiers of the chromatin. Indeed, the plethora of enzymes catalyzing these modifications, portray the diversity of epigenetic space and the intricacy in regulating gene expression. These epigenetic players are categorized as writers: that introduce various chemical modifications on DNA and histones, readers: the specialized domain containing proteins that identify and interpret those modifications and erasers: the dedicated group of enzymes proficient in removing these chemical tags. Research over the past few decades has established that these epigenetic tools are associated with numerous disease conditions especially cancer. Besides, with the involvement of epigenetics in cancer, these enzymes and protein domains provide new targets for cancer drug development. This is certain from the volume of epigenetic research conducted in universities and R&D sector of pharmaceutical industry. Here we have highlighted the different types of epigenetic enzymes and protein domains with an emphasis on methylation and acetylation. This review also deals with the recent developments in small molecule inhibitors as potential anti-cancer drugs targeting the epigenetic space.

AB - Addition of chemical tags on the DNA and modification of histone proteins impart a distinct feature on chromatin architecture. With the advancement in scientific research, the key players underlying these changes have been identified as epigenetic modifiers of the chromatin. Indeed, the plethora of enzymes catalyzing these modifications, portray the diversity of epigenetic space and the intricacy in regulating gene expression. These epigenetic players are categorized as writers: that introduce various chemical modifications on DNA and histones, readers: the specialized domain containing proteins that identify and interpret those modifications and erasers: the dedicated group of enzymes proficient in removing these chemical tags. Research over the past few decades has established that these epigenetic tools are associated with numerous disease conditions especially cancer. Besides, with the involvement of epigenetics in cancer, these enzymes and protein domains provide new targets for cancer drug development. This is certain from the volume of epigenetic research conducted in universities and R&D sector of pharmaceutical industry. Here we have highlighted the different types of epigenetic enzymes and protein domains with an emphasis on methylation and acetylation. This review also deals with the recent developments in small molecule inhibitors as potential anti-cancer drugs targeting the epigenetic space.

UR - http://www.scopus.com/inward/record.url?scp=85052752600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052752600&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2018.08.021

DO - 10.1016/j.ejphar.2018.08.021

M3 - Review article

VL - 837

SP - 8

EP - 24

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -